Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tirvalimogene teraplasmid + pembrolizumab
- Development stage
- Phase 2
- Lead developer
- Genexine
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
**tirvalimogene teraplasmid + pembrolizumab** is a combination therapy for advanced or recurrent cervical cancer, particularly in patients with HPV-16 or HPV-18 positivity. **tirvalimogene teraplasmid (GX-188E)** is a therapeutic DNA vaccine encoding the E6 and E7 oncoproteins of HPV-16 and HPV-18, designed to induce HPV-specific T-cell responses. **pembrolizumab** is a monoclonal antibody that inhibits PD-1, an immune checkpoint receptor, thus enhancing anti-tumor T-cell activity. The combination has demonstrated improved objective response rates compared to pembrolizumab monotherapy in this population, with manageable safety and promising efficacy in clinical trials[1][2][3].
- Other names
- GX-188E + pembrolizumab
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)PDCD1 (Programmed cell death protein 1 receptor)E6/E7 (HPV E6/E7 oncoproteins)E7 (Papillomavirus E6/E7 oncoproteins)
Beyond the preview
Go deeper on tirvalimogene teraplasmid + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tirvalimogene teraplasmid + pembrolizumab.